CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer

• 作者: Xue Yang
• 来源期刊: 药物联合治疗
• 学科: 医学
• 关键词: BREAST cancer CDK4/6 INHIBITORS ENDOCRINE resistance Palbociclib Ribociclib Abemaciclib
• 年，卷（期）: 2020,（1）
• 页码范围: 25-33
• 页数: 9页
• 分类号: R73

摘要

Endocrine therapy(ET)is the therapy backbone of hormone receptor(HR)-positive and human epidermal growth factor receptor 2(HER2)-negati ve advanced breast cancer.However,there are about 20%HR positive patients with no response to ET due to primary or acquired ET resistance.In this background,many agents have been studied to overcome ET resistance and of which the important agents are cyclin-dependent kinase 4/6(CDK4/6)inhibitors.The prognosis of advanced breast cancer has been improved by combing ET with CDK4/6 inhibitors.In this review,we mainly focused on the CDK4/6 inhibitors in the treatment of HR-positive,HER2-negative advanced breast cancer and discussed the action mechanisms of CDK4/6 inhibitors alone or combined with ET.We also summarized several molecular features that would predict response or resistance to CDK4/6 inhibitors.In addition,we put forward possible strategies to overcome CDK4/6 inhibitor resistance according to the latest research.